A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)
Clinical trial NCT00072969 · COMPLETED
Trial details
- NCT number
- NCT00072969
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2003-11-01
- Enrollment
- 132
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.